TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30713786

Group type: EXPERIMENTAL
Intervention: ONCOS-102
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ONCOS-102 and pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab (200 µg or 400 µg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body weight loss and metastasis
Number of subjects: 0
Study: 30713992

Group type: EXPERIMENTAL
Intervention: Supernumerary sex chromosomes
Number of subjects: 0
Study: 30714026

Group type: EXPERIMENTAL
Intervention: Pharmacist-led, technology-aided intervention
Number of subjects: 60
Study: 30714080

Group type: EXPERIMENTAL
Intervention: Group brainstorming session A
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group brainstorming session B
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group brainstorming session C
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combinations of two sessions (A+B, A+C, B+C)
Number of subjects: 52
Study: 30714174

Group type: EXPERIMENTAL
Intervention: rAAV-hG6PC-S298C vector
Number of subjects: 0

Group type: COMPARATOR
Intervention: rAAV-hG6PC-WT vector
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rAAV-co-hG6PC vector
Number of subjects: 0
Study: 30714202

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus clinical management
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clinical management only
Number of subjects: 80
Study: 30714570

Group type: EXPERIMENTAL
Intervention: Fenestrated-branched endovascular aneurysm repair (F-BEVAR)
Number of subjects: 159
Study: 30714833

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30714987

Group type: EXPERIMENTAL
Intervention: Neoantigen screening for TP53 mutations
Number of subjects: 0
Study: 30715229

Group type: EXPERIMENTAL
Intervention: Active HCV
Number of subjects: 327

Group type: COMPARATOR
Intervention: Sustained virologic response (SVR)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Post-SVR
Number of subjects: 327
Study: 30715232

Group type: EXPERIMENTAL
Intervention: Cortical Thickness (CT)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Multimodal association cortex and language centers
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Shared genetic factors
Number of subjects: 813
Study: 30715588

Group type: EXPERIMENTAL
Intervention: Body composition markers
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Skeletal muscle mass index (SMI)
Number of subjects: 1121
Study: 30715944

Group type: EXPERIMENTAL
Intervention: Shockwave Coronary Intravascular Lithotripsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30716132

Group type: EXPERIMENTAL
Intervention: Knee extension force
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Elbow flexion force
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Physical quality of life
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mental quality of life
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Disease duration
Number of subjects: 48
Study: 30716769

Group type: EXPERIMENTAL
Intervention: Compounded pain creams for neuropathic pain (ketamine, gabapentin, clonidine, and lidocaine)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Compounded pain creams for nociceptive pain (ketoprofen, baclofen, cyclobenzaprine, and lidocaine)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Compounded pain creams for mixed pain (ketamine, gabapentin, diclofenac, baclofen, cyclobenzaprine, and lidocaine)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: All treatment groups (compounded pain creams)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo creams
Number of subjects: 399
Study: 30717046

Group type: EXPERIMENTAL
Intervention: Monitored Anesthesia Care (MAC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 30717050

Group type: EXPERIMENTAL
Intervention: Implantable ultrasound device
Number of subjects: 15
Study: 30717616

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 33024
Study: 30717697

Group type: EXPERIMENTAL
Intervention: First stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recurrent strokes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All strokes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevalence of stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incident cases of stroke
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age group 90 years and above
Number of subjects: 0
Study: 30717745

Group type: EXPERIMENTAL
Intervention: Routine Electronic Monitoring of Health-Related Quality of Life (REMOQOL) using electronic patient-reported outcomes (e-PRO)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Physicians' satisfaction with REMOQOL
Number of subjects: 56
Study: 30717802

Group type: EXPERIMENTAL
Intervention: MRX34 (miR-34a mimics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-34a
Number of subjects: 0
Study: 30718102

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily)
Number of subjects: 43
Study: 30718242

Group type: EXPERIMENTAL
Intervention: Malglycemia (hypoglycemia, hyperglycemia, and/or glycemic variability)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Day 0 to 100 mean glucose of 100 to 124 mg/dL
Number of subjects: 344
Study: 30718519

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid/long-acting β agonists prescribed as per usual clinical practice
Number of subjects: 4491

Group type: COMPARATOR
Intervention: Not applicable (observational study)
Number of subjects: 4491
Study: 30718541

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orexin 1 (OX) related intervention
Number of subjects: 0
Study: 30718808

Group type: EXPERIMENTAL
Intervention: Minimally expanded TILs (Young TILs) established from patients with OC.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Adoptive cell transfer (ACT) with TILs.
Number of subjects: 33
Study: 30718945

Group type: EXPERIMENTAL
Intervention: Patient-Reported Experience Measures (PREMs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerized Adaptive Testing (CAT)
Number of subjects: 0
Study: 30719273

Group type: EXPERIMENTAL
Intervention: Antithyroid drugs
Number of subjects: 0
Study: 30719425

Group type: EXPERIMENTAL
Intervention: Ilixadencel (10 × 10^6 cells)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ilixadencel combined with Sorafenib
Number of subjects: 17
Study: 30719976

Group type: EXPERIMENTAL
Intervention: Absorb (bioresorbable scaffold)
Number of subjects: 388

Group type: COMPARATOR
Intervention: EES (everolimus-eluting metallic stents)
Number of subjects: 388
Study: 30720439

Group type: EXPERIMENTAL
Intervention: Text messaging (SMS) reminders; 3 reminders to visit primary care physician.
Number of subjects: 470

Group type: COMPARATOR
Intervention: Routine care (control group); alert to physician regarding positive FOBT result.
Number of subjects: 470

Group type: COMPARATOR
Intervention: Text messaging (SMS) reminders vs. control (routine care).
Number of subjects: 470
Study: 30720689

Group type: EXPERIMENTAL
Intervention: Haploidentical-related donor HSCT performed 2 months after liver transplantation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Left-lobe orthotopic liver transplant
Number of subjects: 1
Study: 30720781

Group type: EXPERIMENTAL
Intervention: High Intensity Physical Activity (HIPA) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fundamental Movement Skill (FMS) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical Activity Signposting (PASS) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30720784

Group type: EXPERIMENTAL
Intervention: Park prescription intervention including an information pack, access to a weekly group exercise program in parks, and telephone counselling.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 0
Study: 30721110

Group type: EXPERIMENTAL
Intervention: Pertuzumab and Trastuzumab (PT)
Number of subjects: 88
Study: 30721341

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg
Number of subjects: 88
Study: 30721531

Group type: EXPERIMENTAL
Intervention: Maternal holding during therapeutic hypothermia
Number of subjects: 10
Study: 30721554

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin (hscTnT) ≤ 5 ng/L
Number of subjects: 3392

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin (hscTnT) > 50 ng/L
Number of subjects: 3392

Group type: EXPERIMENTAL
Intervention: Natriuretic peptide (NT-proBNP) ≤ 125 ng/L
Number of subjects: 3392

Group type: EXPERIMENTAL
Intervention: Natriuretic peptide (NT-proBNP) > 2,000 ng/L
Number of subjects: 3392
Study: 30721721

Group type: COMPARATOR
Intervention: 40 Gy in 5 fractions
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 45 Gy in 5 fractions
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 50 Gy in 5 fractions
Number of subjects: 26
Study: 30721917

Group type: EXPERIMENTAL
Intervention: Single dose of acidified milk (800 g) containing 38.8 g lactose
Number of subjects: 14
Study: 30721972

Group type: EXPERIMENTAL
Intervention: Maternal nutritional interventions
Number of subjects: 0
Study: 30722097

Group type: EXPERIMENTAL
Intervention: 250 mg azithromycin thrice weekly for 12 weeks
Number of subjects: 30
Study: 30722718

Group type: EXPERIMENTAL
Intervention: Peripheral endovascular device intervention
Number of subjects: 1204
Study: 30722822

Group type: EXPERIMENTAL
Intervention: Clostridium histolyticum collagenase
Number of subjects: 159
Study: 30722827

Group type: EXPERIMENTAL
Intervention: Gastric bypass or sleeve gastrectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-risk category based on psychosocial assessment
Number of subjects: 40
Study: 30723059

Group type: EXPERIMENTAL
Intervention: Guideline-adherent care
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Documenting menopausal status
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Ordering diagnostic studies and referrals for postmenopausal women
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Documenting bleeding patterns
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Documenting whether there was active bleeding
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Performing thyroid testing
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Performing a pelvic examination
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Ordering diagnostic studies and referrals in younger women with increased endometrial cancer risk
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Assessing for pregnancy
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Assessing for cervical motion, uterine, or adnexal tenderness in patients with intrauterine devices
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Assessing for elevated endometrial cancer risk
Number of subjects: 305

Group type: COMPARATOR
Intervention: Overall guideline adherence by VA Designated Women's Health Providers
Number of subjects: 305

Group type: COMPARATOR
Intervention: Overall guideline adherence by provider volume of encounters with women veterans
Number of subjects: 305
Study: 30723079

Group type: EXPERIMENTAL
Intervention: Serum levels of sCD163 at the time of interim PET (PET2)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Serum levels of TARC, MDC, and IL-10 after therapy
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Serum levels of TARC and IL-10 after therapy
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Posttherapy levels of TARC and IL-10 in PET2-negative patients
Number of subjects: 559
Study: 30723407

Group type: EXPERIMENTAL
Intervention: Platelet-derived microparticles from obese individuals
Number of subjects: 0
Study: 30723455

Group type: EXPERIMENTAL
Intervention: Unidirectional rotations
Number of subjects: 0
Study: 30723727

Group type: EXPERIMENTAL
Intervention: Observational study data collection including clinical assessments, spirometry, biospecimens, patient-reported outcomes (PROs), and healthcare utilization (HCU) collected yearly and 3-monthly.
Number of subjects: 12000
Study: 30723839

Group type: EXPERIMENTAL
Intervention: Lymph Node Yield (LNY)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymph Node Ratio (LNR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall Survival (OS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease Specific Survival (DSS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progression Free Survival Hazard Ratios (HR)
Number of subjects: 0
Study: 30723894

Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ofatumumab 500 mg
Number of subjects: 51
Study: 30724096

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elagolix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leuprolide acetate
Number of subjects: 0
Study: 30724101

Group type: EXPERIMENTAL
Intervention: Modified texture food use
Number of subjects: 0
Study: 30724333

Group type: EXPERIMENTAL
Intervention: CPAP adherence (defined as CPAP use 4 hours or more per night over 1 year)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CPAP adherence (MCI +CPAP)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MCI +CPAP
Number of subjects: 54

Group type: COMPARATOR
Intervention: MCI -CPAP (control group)
Number of subjects: 54
Study: 30724422

Group type: EXPERIMENTAL
Intervention: Episodic treatment
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment
Number of subjects: 94
Study: 30724423

Group type: EXPERIMENTAL
Intervention: Capmatinib capsules (100 mg q.d. to 600 mg b.i.d.)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Capmatinib tablets (200 mg b.i.d. and 400 mg b.i.d.)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Capmatinib (both formulations)
Number of subjects: 44
Study: 30724735

Group type: EXPERIMENTAL
Intervention: Digital educational program (4-week online program with written information, videos, and social networking features)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Digital educational program
Number of subjects: 25
Study: 30724734

Group type: EXPERIMENTAL
Intervention: EA-230 (90 mg/kg/hour)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 30724759

Group type: EXPERIMENTAL
Intervention: Once-daily oral extended-release bupropion (BRP, Welbutrin XL, 450 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Smartphone video dosing
Number of subjects: 49
Study: 30725293

Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF) therapy for 144 weeks
Number of subjects: 579
Study: 30725402

Group type: EXPERIMENTAL
Intervention: BI 853520 200 mg QD
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BI 853520
Number of subjects: 21
Study: 30726108

Group type: EXPERIMENTAL
Intervention: Normocytic anemia
Number of subjects: 1789
Study: 30726175

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg every 3 weeks for up to 2 years)
Number of subjects: 50
Study: 30726184

Group type: EXPERIMENTAL
Intervention: Good collaterals
Number of subjects: 130

Group type: COMPARATOR
Intervention: Poor collaterals
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 130
Study: 30727950

Group type: EXPERIMENTAL
Intervention: Male partners receiving syphilis notification and treatment after partner notification by infected pregnant women.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Public messaging about syphilis and improved services.
Number of subjects: 54
Study: 30728140

Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 53
Study: 30728310

Group type: EXPERIMENTAL
Intervention: robot-based therapy targeting finger movements with enhanced proprioceptive feedback for 3 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Measures related to the somatosensory network
Number of subjects: 30
Study: 30728923

Group type: EXPERIMENTAL
Intervention: Exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells
Number of subjects: 0
Study: 30729028

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg/day
Number of subjects: 55
Study: 30729531

Group type: EXPERIMENTAL
Intervention: CD19-directed CAR T-cell therapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Age (every 10-year increase)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Disease type (CLL vs. ALL)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Disease type (NHL vs. ALL)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Precollection platelets (every 10 × 10^9/L increase)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Lymphocyte collection efficiency (CE)
Number of subjects: 92
Study: 30729729

Group type: COMPARATOR
Intervention: Postural sway measured as AP range during quiet standing with eyes closed on day 3
Number of subjects: 31

Group type: COMPARATOR
Intervention: Postural sway measured as variability during quiet standing with eyes closed on day 3
Number of subjects: 31

Group type: COMPARATOR
Intervention: Complexity index of AP COP on day 3
Number of subjects: 31

Group type: COMPARATOR
Intervention: Complexity index of AP COP on day 21
Number of subjects: 31

Group type: COMPARATOR
Intervention: Complexity index of AP COP on day 90
Number of subjects: 31
Study: 30730031

Group type: EXPERIMENTAL
Intervention: Eye tracking and psychophysiological metrics (using E4 wearable wristband)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Visual stimulus task measuring attentional capacity
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Electrodermal activity (EDA) measurements
Number of subjects: 2
Study: 30730411

Group type: EXPERIMENTAL
Intervention: Germline genetic counseling and multipanel gene testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Close prostate specific antigen screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeting PARP enzymes in metastatic, castration resistant prostate cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors in cancers with increased tumor mutational burden
Number of subjects: 0
Study: 30730782

Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus followed by a 2-hour infusion)
Number of subjects: 352
Study: 30730923

Group type: EXPERIMENTAL
Intervention: NIH Image J software
Number of subjects: 101

Group type: COMPARATOR
Intervention: SliceOmatic
Number of subjects: 101
Study: 30731276

Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg intravenously every 2 weeks for 12 months
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 62
Study: 30731280

Group type: EXPERIMENTAL
Intervention: Atypical depression in probands
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: BMI/overweight in probands
Number of subjects: 837
Study: 30732551

Group type: EXPERIMENTAL
Intervention: Elevated brain oxygen extraction fraction (OEF) measured by MRI susceptibility in the affected hemisphere (29.3 ± 3.4%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Contralateral hemisphere OEF (25.5 ± 3.1%)
Number of subjects: 20
Study: 30732640

Group type: EXPERIMENTAL
Intervention: 3D-Conformal Radiotherapy (RT) for left-sided BC patients
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 3D-Conformal Radiotherapy (RT) for right-sided BC patients
Number of subjects: 104
Study: 30732844

Group type: EXPERIMENTAL
Intervention: 4-week Mindfulness-Based Attention Training (MBAT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2-week Mindfulness-Based Attention Training (MBAT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Attention Training (MBAT) (both durations)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No Training Control (NTC)
Number of subjects: 120
Study: 30733270

Group type: EXPERIMENTAL
Intervention: Twice-weekly carfilzomib at 27 mg/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-weekly carfilzomib at 56 mg/m2
Number of subjects: 0
Study: 30733683

Group type: EXPERIMENTAL
Intervention: 1-year Mediterranean type diet
Number of subjects: 1250
Study: 30733874

Group type: EXPERIMENTAL
Intervention: Pigtail probe followed by self-retaining silicone bicanalicular stent insertion for 6 months
Number of subjects: 24
Study: 30734042

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy plus standard medical therapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 182
Study: 30735141

Group type: EXPERIMENTAL
Intervention: EVIDENT smartphone app
Number of subjects: 362

Group type: COMPARATOR
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 362
Study: 30735255

Group type: EXPERIMENTAL
Intervention: Acute intravenous alcohol infusion
Number of subjects: 24
Study: 30735342

Group type: EXPERIMENTAL
Intervention: Home-time (days spent at home for the first 90 days after aSAH)
Number of subjects: 1076
Study: 30735474

Group type: EXPERIMENTAL
Intervention: Tdap vaccine adoption at no-cost
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Tdap vaccine adoption with cost (25€ per person)
Number of subjects: 615
Study: 30735593

Group type: EXPERIMENTAL
Intervention: Risk-reducing early salpingectomy and delayed oophorectomy
Number of subjects: 0
Study: 30736150

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study: 30736445

Group type: EXPERIMENTAL
Intervention: Low saturated fat diet (Swank)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Paleolithic diet (WahlsElim)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30736779

Group type: EXPERIMENTAL
Intervention: Web-based questionnaire assessing PRMDs and risk factors
Number of subjects: 3000
Study: 30736818

Group type: EXPERIMENTAL
Intervention: CRP point-of-care test intervention
Number of subjects: 130
Study: 30736848

Group type: EXPERIMENTAL
Intervention: BI1361849 (CV9202) combined with local radiation (4 × 5 Gy)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BI1361849 (CV9202)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BI1361849 (CV9202) with pemetrexed maintenance
Number of subjects: 26
Study: 30736852

Group type: EXPERIMENTAL
Intervention: Allogenic γδ T cell immunotherapy (8 infusions from August 2017 to February 2018)
Number of subjects: 1